Fractyl Health’s Revita shows improvement in Type 2 diabetes in German study

Fractyl Health announced 6-month follow-up data from its enrolling German real-world registry study of Revita for type 2 diabetes, or T2D. The first 14 consented registry participants have now completed at least 6 months of post-Revita follow up. Despite using up to three different glucose lowering medications, participants’ T2D remained uncontrolled with a median baseline HbA1c of 9.2%. These 14 participants underwent Revita and experienced an average total body weight loss of 8.1% at 6 months after the procedure, with generally sustained or improved weight loss from month 1 to month 6. Fasting blood glucose also improved after the procedure, reflecting better glucose control, despite all patients stabilizing or reducing the number of glucose-lowering medications. No device or procedure-related serious adverse events have been reported to date. The West German Diabetes Center of Excellence offering Revita combined with dietary and lifestyle support in Dusseldorf, Germany recently presented the Revita registry study 3-month follow-up results.